Australia's most trusted
source of pharma news
Wednesday, 29 October 2025
Posted 29 October 2025 AM
A November PBS listing will open the door to subsidised access to Boehringer Ingelheim's Jardiance for 70,000 Australians living with chronic kidney disease (CKD).
The listing addresses Australia's spiralling rates of hospitalisation, dialysis and transplant - and more than doubles the size of the current patient population eligible for treatment with the drug.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.